Tuberculosis Drug Discovery and Development 2019
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main c...
Gardado en:
| Formato: | Online |
|---|---|
| Idioma: | inglés |
| Publicado: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Acceso en liña: | ONIX_20210501_9783039432363_1078 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
| _version_ | 1869516978835685376 |
|---|---|
| collection | Directory of Open Access Books |
| description | Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue. |
| format | Online |
| id | doab-20.500.12854ir-69332 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-693322024-03-28T03:33:15Z Tuberculosis Drug Discovery and Development 2019 Riccardi, Giovanna Sala, Claudia mycobacteria tuberculosis multi-drug resistance drug discovery promiscuous targets Mycobacterium tuberculosis rifampin isoniazid mechanisms of resistance mutations granulomas caseum cell envelope dormancy delpazolid macozinone DprE1 inhibitor clinical studies discovery mode of action drug resistance toxicity target energy metabolism electron transport chain oxidative phosphorylation bedaquiline Q203 MID3 pharmacokinetics pharmacodynamics drug-drug interactions in vitro in vivo drug development tuberculosis treatment biomarkers drug combination clinical trial BCG tuberculosis vaccines TBVI EDCTP IAVI CTVD host-directed therapy anti-virulence compounds TB post-treatment sequelae surgery pulmonary rehabilitation Carlo Forlanini artificial pneumothorax n/a structure-based drug design target-based drug design PknB PknG DNA gyrase antibiotic mycobacterium genomics transcriptomics proteomics metabolomics lipidomics target identification mechanism of action antimicrobial drug resistance (AMR) target-based screening phenotypic screening antituberculosis agents antimycobacterial anti-TB drug pipeline privileged targets lead generation thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue. 2021-05-01T15:46:55Z 2021-05-01T15:46:55Z 2020 book ONIX_20210501_9783039432363_1078 9783039432363 9783039432370 https://directory.doabooks.org/handle/20.500.12854/69332 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/3124 https://mdpi.com/books/pdfview/book/3124 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03943-237-0 10.3390/books978-3-03943-237-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039432363 9783039432370 296 Basel, Switzerland open access |
| spellingShingle | mycobacteria tuberculosis multi-drug resistance drug discovery promiscuous targets Mycobacterium tuberculosis rifampin isoniazid mechanisms of resistance mutations granulomas caseum cell envelope dormancy delpazolid macozinone DprE1 inhibitor clinical studies discovery mode of action drug resistance toxicity target energy metabolism electron transport chain oxidative phosphorylation bedaquiline Q203 MID3 pharmacokinetics pharmacodynamics drug-drug interactions in vitro in vivo drug development tuberculosis treatment biomarkers drug combination clinical trial BCG tuberculosis vaccines TBVI EDCTP IAVI CTVD host-directed therapy anti-virulence compounds TB post-treatment sequelae surgery pulmonary rehabilitation Carlo Forlanini artificial pneumothorax n/a structure-based drug design target-based drug design PknB PknG DNA gyrase antibiotic mycobacterium genomics transcriptomics proteomics metabolomics lipidomics target identification mechanism of action antimicrobial drug resistance (AMR) target-based screening phenotypic screening antituberculosis agents antimycobacterial anti-TB drug pipeline privileged targets lead generation thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Tuberculosis Drug Discovery and Development 2019 |
| title | Tuberculosis Drug Discovery and Development 2019 |
| title_full | Tuberculosis Drug Discovery and Development 2019 |
| title_fullStr | Tuberculosis Drug Discovery and Development 2019 |
| title_full_unstemmed | Tuberculosis Drug Discovery and Development 2019 |
| title_short | Tuberculosis Drug Discovery and Development 2019 |
| title_sort | tuberculosis drug discovery and development 2019 |
| topic | mycobacteria tuberculosis multi-drug resistance drug discovery promiscuous targets Mycobacterium tuberculosis rifampin isoniazid mechanisms of resistance mutations granulomas caseum cell envelope dormancy delpazolid macozinone DprE1 inhibitor clinical studies discovery mode of action drug resistance toxicity target energy metabolism electron transport chain oxidative phosphorylation bedaquiline Q203 MID3 pharmacokinetics pharmacodynamics drug-drug interactions in vitro in vivo drug development tuberculosis treatment biomarkers drug combination clinical trial BCG tuberculosis vaccines TBVI EDCTP IAVI CTVD host-directed therapy anti-virulence compounds TB post-treatment sequelae surgery pulmonary rehabilitation Carlo Forlanini artificial pneumothorax n/a structure-based drug design target-based drug design PknB PknG DNA gyrase antibiotic mycobacterium genomics transcriptomics proteomics metabolomics lipidomics target identification mechanism of action antimicrobial drug resistance (AMR) target-based screening phenotypic screening antituberculosis agents antimycobacterial anti-TB drug pipeline privileged targets lead generation thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| topic_facet | mycobacteria tuberculosis multi-drug resistance drug discovery promiscuous targets Mycobacterium tuberculosis rifampin isoniazid mechanisms of resistance mutations granulomas caseum cell envelope dormancy delpazolid macozinone DprE1 inhibitor clinical studies discovery mode of action drug resistance toxicity target energy metabolism electron transport chain oxidative phosphorylation bedaquiline Q203 MID3 pharmacokinetics pharmacodynamics drug-drug interactions in vitro in vivo drug development tuberculosis treatment biomarkers drug combination clinical trial BCG tuberculosis vaccines TBVI EDCTP IAVI CTVD host-directed therapy anti-virulence compounds TB post-treatment sequelae surgery pulmonary rehabilitation Carlo Forlanini artificial pneumothorax n/a structure-based drug design target-based drug design PknB PknG DNA gyrase antibiotic mycobacterium genomics transcriptomics proteomics metabolomics lipidomics target identification mechanism of action antimicrobial drug resistance (AMR) target-based screening phenotypic screening antituberculosis agents antimycobacterial anti-TB drug pipeline privileged targets lead generation thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| url | ONIX_20210501_9783039432363_1078 |